QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:VRNA

Verona Pharma (VRNA) Stock Forecast, Price & News

$16.56
-0.01 (-0.06%)
(As of 09/25/2023 ET)
Compare
Today's Range
$16.38
$16.79
50-Day Range
$16.57
$22.09
52-Week Range
$8.41
$26.44
Volume
221,903 shs
Average Volume
469,345 shs
Market Capitalization
$10.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.60

Verona Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
96.9% Upside
$32.60 Price Target
Short Interest
Bearish
0.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.46 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.86) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

898th out of 961 stocks

Pharmaceutical Preparations Industry

425th out of 452 stocks


VRNA stock logo

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Price History

VRNA Stock News Headlines

Wedbush Reiterates Outperform Rating for Verona Pharma (NASDAQ:VRNA)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Verona Pharma (VRNA) Receives a Buy from H.C. Wainwright
Verona Pharma: Targeting The Large COPD Market
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma Plc (NASDAQ: VRNA)
Wedbush Remains a Buy on Verona Pharma (VRNA)
Truist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)
VRNA - Verona Pharma plc
Verona Pharma (VRNA) Gets a Buy from H.C. Wainwright
Massive Insider Trade At Verona Pharma
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings
8/03/2023
Today
9/25/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.60
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+96.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-68,700,000.00
Pretax Margin
-11,151.31%

Debt

Sales & Book Value

Annual Sales
$460,000.00
Price / Sales
22,884.12
Book Value
$3.05 per share

Miscellaneous

Free Float
610,879,000
Market Cap
$10.53 billion
Optionable
Not Optionable
Beta
0.21
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. David S. ZaccardelliDr. David S. Zaccardelli (Age 58)
    Pres, CEO & Exec. Director
    Comp: $1.05M
  • Mr. Mark W. HahnMr. Mark W. Hahn (Age 60)
    Chief Financial Officer
    Comp: $784.38k
  • Dr. Kathleen A. RickardDr. Kathleen A. Rickard (Age 65)
    Chief Medical Officer
    Comp: $655k
  • Ms. Claire Louise Poll L.C.S.W. (Age 56)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Mr. Matthew Casbon
    VP of Sales, Marketing & Training
  • Ms. Ostra Jewell
    Sr. VP of HR
  • Dr. Peter Spargo (Age 61)
    Sr. VP of Chemistry Manufacturing & Controls
  • Dr. Tara Rheault M.P.H. (Age 46)
    Ph.D., Sr. VP of R&D
  • Mr. Christopher Martin
    Sr. VP of Commercial













VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price forecast for 2023?

5 equities research analysts have issued 12 month price targets for Verona Pharma's shares. Their VRNA share price forecasts range from $31.00 to $35.00. On average, they expect the company's stock price to reach $32.60 in the next year. This suggests a possible upside of 96.9% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2023?

Verona Pharma's stock was trading at $26.13 at the beginning of the year. Since then, VRNA stock has decreased by 36.6% and is now trading at $16.56.
View the best growth stocks for 2023 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our VRNA earnings forecast
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.16.

What ETF holds Verona Pharma's stock ?

ALPS Medical Breakthroughs ETF holds 60,171 shares of VRNA stock, representing 1.19% of its portfolio.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.22%), Nicholas Investment Partners LP (0.18%), Bellevue Group AG (0.09%), Woodline Partners LP (0.08%), Affinity Asset Advisors LLC (0.07%) and BlackRock Inc. (0.06%). Insiders that own company stock include Anders Ullman, Claire Poll, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends
.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $16.56.

How much money does Verona Pharma make?

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $10.53 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -